PDCD1 and neoplasm: Alongside, preclinical data in mouse models [62], and data of a phase 1 basket trial (NCT02009449) using pegylated IL-10 for treatment of solid cancer, demonstrated that IL-10 helps to maintain CD8+ T cell-mediated tumor control and improves patients’ responses to PD-1 blockade [63].